mdt-20260901 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   _____________________________  FORM 8-K   _____________________________  CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2026   _____________________________  Medtronic plc (Exact name of Registrant as Specified in its Charter)    _____________________________    Ireland 1-36820 98-1183488 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) Building Two Parkmore Business Park West Galway , Ireland (Address of principal executive offices) (Zip Code) + 353 1 438-1700 (Registrant’s telephone number, including area code) Not Applicable Former name or former address, if changed since last report Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol Name of each exchange on which registered Ordinary shares, par value $0.0001 per share MDT New York Stock Exchange 1.125% Senior Notes due 2027 MDT/27 New York Stock Exchange 0.375% Senior Notes due 2028 MDT/28 New York Stock Exchange 3.000% Senior Notes due 2028 MDT/28A New York Stock Exchange 3.650% Senior Notes due 2029 MDT/29 New York Stock Exchange 2.950% Senior Notes due 2030 MDT/30 New York Stock Exchange 1.625% Senior Notes due 2031 MDT/31 New York Stock Exchange 1.000% Senior Notes due 2031 MDT/31A New York Stock Exchange 3.125% Senior Notes due 2031 MDT/31B New York Stock Exchange 0.750% Senior Notes due 2032 MDT/32 New York Stock Exchange 3.375% Senior Notes due 2034 MDT/34 New York Stock Exchange 3.875% Senior Notes due 2036 MDT/36 New York Stock Exchange 2.250% Senior Notes due 2039 MDT/39A New York Stock Exchange 1.500% Senior Notes due 2039 MDT/39B New York Stock Exchange 1.375% Senior Notes due 2040 MDT/40A New York Stock Exchange 4.150% Senior Notes due 2043 MDT/43A New York Stock Exchange 4.200% Senior Notes due 2045 MDT/45 New York Stock Exchange 1.750% Senior Notes due 2049 MDT/49 New York Stock Exchange 1.625% Senior Notes due 2050 MDT/50 New York Stock Exchange 4.150% Senior Notes due 2053 MDT/53 New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition On September 1, 2026, Medtronic plc, a public limited company organized under the laws of Ireland, issued a press release announcing its first quarter fiscal year 2027 financial results. A copy of the press release is furnished as Exhibit 99.1 to this report. Item 9.01. Exhibits. (d) List of Exhibits Exhibit Number    Description 99.1    Press release of Medtronic plc, dated September 1, 2026 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Medtronic plc By /s/ Thierry Piéton Date: September 1, 2026 Thierry Piéton Executive Vice President and Chief Financial Officer (Principal Financial Officer) EXHIBIT INDEX Exhibit Number    Description 99.1    Press release of Medtronic plc, dated September 1, 2026 104 Cover Page Interactive Data File (embedded with the Inline XBRL document). EX-99.1 2 exhibit991-fy27q1earningsr.htm EX-99.1 Document Exhibit 99.1 NEWS RELEASE FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2027 results; delivers broad-based portfolio performance and raises fiscal 2027 guidance Strength across the company’s largest franchises, new growth platforms, and recent portfolio investments support the long-term growth trajectory GALWAY, Ireland – September 1, 2026 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2027 (FY27), which ended July 31, 2026. Key Highlights • Revenue of $9.8 billion, increased 13.7% as reported and 13.7% organic, roughly 200 basis points above guidance midpoint • GAAP diluted EPS of $1.14; non-GAAP diluted EPS of $1.45, ahead of guidance • Raising FY27 organic revenue growth guidance 50 basis points to 7.25% to 7.75%, and FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 • Cardiovascular grew 18.9%, led by 15% growth in Cardiac Rhythm Management and 88% growth in Cardiac Ablation Solutions 1 • Announced expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias • Announces strategic investment in Pi-Cardia, a pioneer in leaflet modification technology • Neuroscience grew 9.3%, driven by 13% growth in Cranial and Spinal Technologies, including low-20s growth in enabling technology; Altaviva meaningfully contributed to 15% growth in Pelvic Health • Medical Surgical reported strong performance, up 10.2%, led by 9% growth in Surgical and 14% growth in Acute Care & Monitoring • Announces strategic partnership with Cornerstone Robotics to further expand global access to robotic-assisted surgery • Announced FDA clearance for Touch Surgery™ Aide next generation computing platform • Completed acquisitions of Scientia Vascular and SPR Therapeutics, Inc. “We are off to a strong start in fiscal 2027. What gives us confidence is not simply the strength of the quarter, but importantly, the breadth of performance across our businesses and the increasing contributions from newer growth platforms,” said Geoff Martha, Medtronic chairman and chief executive officer. “Our execution, alongside our innovation engine, positions us to serve more patients and deliver durable growth. The strength of our portfolio and pipeline gives us confidence in the opportunities ahead.” Financial Results Medtronic reported Q1 worldwide revenue of $9.756 billion, an increase of 13.7% as reported and 13.7% on an organic basis. The Q1 FY27 organic revenue growth comparison excludes: • Other revenue of $29 million in the current year versus $72 million in the prior year • Revenue from the Dutch Obesity Clinic (NOK) divestiture with no revenue in the current year and $17 million in the prior year 2 • Scientia revenue of $14 million (closed June 12) and SPR Therapeutics revenue of $5 million in the current year (closed July 16) • Foreign exchange benefit of $57 million on the remaining net sales Results were impacted by the extra fiscal week, which occurred in Medtronic’s first quarter of FY27. The company estimates the impact of the extra week benefited Q1 organic growth by approximately $570 million. Q1 revenue included: • Cardiovascular Portfolio revenue of $3.927 billion increased 19.5% as reported and 18.9% organic, with high-20s increase in Electrophysiology Therapies, high-single digit increase in Interventional Cardiology Therapies, high-single digit increase in CardioVascular Surgery, and low-double digit increase in Peripheral Vascular Health, all on an organic basis • Neuroscience Portfolio revenue of $2.678 billion increased 10.3% reported and 9.3% organic, with low-double digit increase in Cranial & Spinal Technologies, high-single digit increase in Specialty Therapies, and low-single digit increase in Neuromodulation, all on an organic basis • Medical Surgical Portfolio revenue of $2.279 billion increased 10.0% as reported and 10.2% organic, with high-single digit increase in Surgical & Endoscopy, and mid-teens increase in Acute Care & Monitoring, all on an organic basis • Diabetes business revenue of $843 million increased 16.9% as reported and 14.9% organic 1 Q1 GAAP operating profit and operating margin were $1.764 billion and 18.1%, respectively, an increase of 22.1% and 120 basis points, respectively. As detailed in the financial schedules included at the end of the release, Q1 non-GAAP operating profit and operating margin were $2.316 billion and 23.7%, respectively, an increase of 14.9% and 10 basis points, respectively. 3 Q1 GAAP net income and diluted earnings per share (EPS) were $1.470 billion and $1.14, respectively, representing increases of 41.4% and 40.7%, respectively. As detailed in the financial schedules included at the end of this release, Q1 non-GAAP net income and non-GAAP diluted EPS were $1.860 billion and $1.45 respectively, representing increases of 14.4% and 15.1%, respectively. Guidance The company today raised its FY27 organic revenue growth and EPS guidance. The company raised its FY27 organic revenue growth guidance to 7.25% to 7.75%, an increase from the prior guidance of 6.75% to 7.25%. The company also raised its FY27 diluted non-GAAP EPS guidance to the new range of $5.94 to $6.00 versus the prior $5.90 to $6.00. This guidance includes an estimated neutral to 1% accretive impact from foreign currency exchange based on recent rates. “We continue to make targeted investments in innovation, portfolio development, and commercial execution that will support sustainable long-term value creation,” said Thierry Piéton, Medtronic chief financial officer. “The combination of strong operating performance and disciplined financial management drove revenue and adjusted EPS ahead of expectations, enabling us to raise our fiscal 2027 guidance.” Video Webcast Information Medtronic will host a video webcast today, September 1, at 7:45 a.m. EST (6:45 a.m. CST) to provide information about its business for the public, investors, analysts, and news media. This webcast can be accessed by clicking on the Quarterly Earnings icon at investorrelations.medtronic.com, and this earnings release will be archived at news.medtronic.com. Within 24 hours of the webcast, a replay of the webcast and transcript of the company’s prepared remarks will be available by clicking on the Past Events and Presentations link under the News & Events drop-down at investorrelations.medtronic.com. 4 Financial Schedules The first quarter financial schedules and non-GAAP reconciliations can be viewed by clicking on the Quarterly Earnings link at investorrelations.medtronic.com. About Medtronic Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn. FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties, including risks related to competitive factors, difficulties and delays inherent in the development, manufacturing, marketing and sale of medical products, government regulation, geopolitical conflicts, changing global trade policies, material acquisition and divestiture transactions, general economic conditions, and other risks and uncertainties described in the company’s periodic reports on file with the U.S. Securities and Exchange Commission including the most recent Annual Report on Form 10-K of the company. In some cases, you can identify these statements by forward-looking words or expressions, such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “looking ahead,” “may,” “plan,” “possible,” “potential,” “project,” “should,” “going to,” “will,” and similar words or expressions, the negative or plural of such words or expressions and other comparable terminology. Actual results may differ materially from anticipated results. Medtronic does not undertake to update its forward-looking statements or any 5 of the information contained in this press release, including to reflect future events or circumstances. NON-GAAP FINANCIAL MEASURES This press release contains guidance and financial measures, including adjusted net income, adjusted diluted EPS, and organic revenue, which are considered “non-GAAP” financial measures under applicable SEC rules and regulations. Certain information in this press release also includes calculations or figures that have been prepared internally and have not been reviewed or audited by our independent registered public accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences and such differences may be material. Medtronic management believes that non-GAAP financial measures provide information useful to investors in understanding the company’s underlying operational performance and trends and to facilitate comparisons with the performance of other companies in the med tech industry. Non-GAAP net income and diluted EPS exclude the effect of certain charges or gains that contribute to or reduce earnings but that result from transactions or events that management believes may or may not recur with similar materiality or impact to operations in future periods (Non-GAAP Adjustments). Medtronic generally uses non-GAAP financial measures to facilitate management’s review of the operational performance of the company and as a basis for strategic planning. Non-GAAP financial measures should be considered supplemental to and not a substitute for financial information prepared in accordance with U.S. generally accepted accounting principles (GAAP), and investors are cautioned that Medtronic may calculate non-GAAP financial measures in a way that is different from other companies. Management strongly encourages investors to review the company’s consolidated financial statements and publicly filed reports in their entirety. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial schedules accompanying this press release. Medtronic calculates forward-looking non-GAAP financial measures based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. For instance, forward-looking organic revenue growth guidance excludes the impact of foreign currency fluctuations, revenue in the current and prior year reported as "Other”, as well as significant acquisitions, divestitures, or other significant discrete items. Forward-looking diluted non-GAAP EPS guidance also excludes other potential charges or gains that would be recorded as Non-GAAP Adjustments to earnings during the fiscal year. Medtronic does not attempt to provide reconciliations of forward-looking non-GAAP EPS guidance to projected GAAP EPS guidance because the combined impact and timing of recognition of these potential charges or gains is 6 inherently uncertain and difficult to predict and is unavailable without unreasonable efforts. In addition, the company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a substantial impact on GAAP measures of financial performance. FINANCIAL COMPARISONS References to quarterly or annual figures increasing, decreasing, or remaining flat are in comparison to fiscal year 2026, and references to sequential changes are in comparison to the prior fiscal quarter. Unless stated otherwise, quarterly and annual rates and ranges are given on an organic basis. References to organic revenue growth exclude the impact of foreign currency, first quarter revenue in the current and prior year reported as "Other”, as well as significant acquisitions, divestitures, or other significant discrete items. TRANSACTION DETAILS The separation of our Diabetes business has involved and is expected to be completed through a series of capital markets transactions, which may include a spin-off, split-off, offering, or combination thereof. While a split-off is the company's current preferred separation structure, a final decision has not been reached at this time. -end- Contacts: Justin Paquette Public Relations +1-612-271-7935 Ingrid Goldberg Investor Relations +1-763-505-2696 ______________________ 1 The Diabetes results presented here may not correspond to the same financial statement information presented by MiniMed Group, Inc. (MiniMed) due to MiniMed’s financials being prepared on a carve out basis through the date of the company’s initial public offering (IPO) and on a standalone basis post IPO. 7 FINANCIAL SCHEDULES Page Worldwide Revenue 9 U.S. Revenue 10 International Revenue 11 Condensed Consolidated Statements of Income 12 GAAP to Non-GAAP Reconciliations 13 Condensed Consolidated Statements of Cash Flows 16 8 MEDTRONIC PLC WORLDWIDE REVENUE (1) (Unaudited) FIRST QUARTER (2) REPORTED ORGANIC (in millions) FY27 FY26 Growth Currency Impact (7) FY27 (8) FY26 (8) Growth Cardiovascular (3) $ 3,927   $ 3,285   19.5   % $ 21   $ 3,906   $ 3,285   18.9   % Electrophysiology Therapies 2,218  1,712  29.5  8  2,210  1,712  29.1  Interventional Cardiology Therapies 894  834  7.2  6  889  834  6.5  CardioVascular Surgery 477  436  9.3  5  472  436  8.1  Peripheral Vascular Health 338  302  11.6  2  336  302  11.0  Neuroscience (3) 2,678   2,427   10.3   6   2,653   2,427   9.3   Cranial & Spinal Technologies 1,365  1,211  12.8  (2) 1,367  1,211  12.9  Specialty Therapies 774  702  10.2  6  754  702  7.4  Neuromodulation (3) 539  514  4.7  2  531  514  3.3  Medical Surgical (3) 2,279   2,073   10.0   15   2,265   2,056   10.2   Surgical & Endoscopy (3) 1,740  1,601  8.7  14  1,726  1,584  9.0  Acute Care & Monitoring 539  471  14.4  1  538  471  14.2  Total Reportable Segments 8,884   7,785   14.1   43   8,823   7,768   13.6   Diabetes (4) 843   721   16.9   14   829   721   14.9   Other (5) 29   72   NM (6) —   —   —   —   TOTAL $ 9,756   $ 8,578   13.7   % $ 57   $ 9,652   $ 8,489   13.7   % See description of non-GAAP financial measures contained in the press release dated September 1, 2026. (1) The data in this schedule has been intentionally rounded to the nearest million and, therefore, may not sum. Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely. (2) Fiscal year 2027 is a 53-week fiscal year, with the extra week occurring in the first fiscal month of the first quarter and included in reported first quarter results. While it is difficult to calculat